Reported Earlier, Pliant Therapeutics Announced The Updated Data From Its Phase 1 Trial Of PLN-101095, In Combination With Pembrolizumab, In Patients With Immune Checkpoint Inhibitor (ICI)-refractory Advanced Or Metastatic Solid Tumors